Algenex

algenex.com ↗ ·Tres Cantos ·Other

Acquired by Insud Pharma, 2022. Algenex no longer appears in the directory or on the maps; its funding history is kept below. Source ↗

Madrid-based biotech (Tres Cantos) founded in 2005 by José Ángel Escribano, developing CrisBio® and TopBac®, proprietary baculovirus-based insect-cell expression platforms used as living bioreactors to produce recombinant proteins and vaccines for human and animal health, therapeutics, and diagnostics. Previously backed by Spanish VC/PE investors, Algenex was acquired by pharmaceutical group Insud Pharma in October 2022, so it now operates as part of that group rather than as an independently VC-fundable startup.

Founded

2005

Founders

Total funds raised

€7.4M

SectorsBiotechnology, Vaccine manufacturing, Recombinant protein production, Life sciences

Suggest a correction

Founders

José Ángel Escribano

Founder & Chief Scientific Officer

Global models 5

Resilience (National Resilience)

United States · resilience.com ↗

VC-backed biomanufacturing platform company producing biologics and vaccines at scale, similar in spirit to Algenex's platform-for-hire approach to protein/vaccine manufacturing.

$2.1BComparable

Ginkgo Bioworks

United States · www.ginkgobioworks.com ↗

Synthetic biology platform that engineers cells to manufacture proteins and other biomolecules for partners, paralleling Algenex's cell-based expression-platform licensing model.

$1.7BComparable

Zymergen

United States · www.zymergen.com ↗

Biomanufacturing platform company using engineered microbes to produce novel proteins and materials, comparable to Algenex's proprietary bioproduction technology model.

$974MComparable

GreenLight Biosciences

United States · greenlightbiosciences.com ↗

Alternative (cell-free RNA) biomanufacturing platform for vaccines and therapeutics, matching Algenex's focus on novel, non-traditional production systems for vaccines.

$600MComparable

Absci

United States · www.absci.com ↗

AI-driven biologics discovery and manufacturing platform serving pharma partners, similar to Algenex's role as a specialized recombinant-protein production technology provider.

$470MComparable